Where Cosmetics Cross Into Drug Territory Under Thai FDA Rules

Thailand's Cosmetics Act B.E. 2558 (2015) defines a cosmetic by what it does, not by what it contains. A product applied to the outer body, hair, teeth, or oral cavity to clean, beautify, promote attractiveness, or maintain the body in good condition, without affecting the structure or function of the body, sits inside the definition. The moment a product's intended function crosses into treating, curing, or altering a physiological function, it stops being a cosmetic under Thai law regardless of what its label calls itself, and starts requiring the far heavier drug registration pathway instead. This function-based test, not an ingredient list, is what actually decides classification in Thailand, and it is also exactly why the boundary trips up more brands than any single ingredient restriction does.

The Test Is About Function and Claim, Not Ingredient Alone

An ingredient that behaves therapeutically in one formulation can sit comfortably inside cosmetic territory in another, because Thai FDA is assessing the product's overall intended use, signaled primarily through its marketing claims, not running an ingredient-by-ingredient therapeutic-potential check. A moisturizer containing salicylic acid marketed to smooth and soften skin reads as a cosmetic. The same acid at the same concentration marketed to treat acne, clear blemishes, or cure a skin condition reads as making a drug claim, because "treat" and "cure" describe an effect on a physiological or pathological condition rather than a cosmetic effect on appearance. Thai FDA's own notification system reinforces this in an easy-to-miss way: the notification process itself does not evaluate whether a product's marketing claims are true or exaggerated at the point of filing. A brand can receive a notification number for a formulation whose accompanying claims already cross into drug territory, because the claims review happens separately, through post-market advertising oversight, not through the notification gate. That separation is precisely why a compliant ingredient list offers no protection against a non-compliant claim; the two are checked by different parts of the system, on different timelines, and only one of them, advertising enforcement, actually looks at what the label and marketing say.

Teeth Whitening as the Clearest Illustration

Teeth whitening products are a useful worked example because Thailand explicitly includes them within the cosmetic definition, provided the product is limited to a cosmetic mode of action, a surface-level effect on the visible appearance of teeth achieved through mechanical or mild chemical means, rather than a claim to correct an underlying dental or medical condition. A whitening toothpaste or gel marketed to remove surface stains and brighten the visible appearance of teeth stays inside cosmetic scope. The same product marketed to treat gum disease, repair enamel damage, or address a diagnosed dental condition has stepped outside it, triggering either drug or medical device classification depending on the specific mechanism claimed. The lesson generalizes well beyond dental care: any product category where a cosmetic effect and a therapeutic effect are only a marketing sentence apart needs its claims reviewed with the same rigor as its formulation.

Where Brands Actually Cross the Line

In practice, the crossing happens in a handful of recurring patterns rather than through deliberate rule-breaking. Acne treatments are the most common, where a formulation built around salicylic acid or benzoyl peroxide gets marketed with language like "treats acne" or "clears breakouts" rather than "helps reduce the appearance of blemishes," turning a cosmetic formulation into an unregistered drug claim overnight. Anti-aging serums slip across the same line when copy promises to "repair" skin damage or "reverse" the aging process, both of which describe a physiological correction rather than a cosmetic improvement in appearance. Hair-loss products are a particularly sharp example because the underlying condition, androgenetic alopecia, is itself a diagnosed medical condition; a shampoo marketed to "strengthen hair" and reduce the appearance of thinning generally stays cosmetic, while the same shampoo marketed to "stop hair loss" or "regrow hair" is making a drug-level claim that Thai FDA and most other regulators worldwide treat as requiring pharmaceutical substantiation. Skin-whitening actives sit in their own gray zone discussed at greater length elsewhere in our coverage, precisely because Thailand regulates the underlying mechanism, melanin suppression, more closely than most cosmetic effects, and a whitening claim pushed too far into "treating hyperpigmentation" or "correcting a skin condition" edges toward drug territory even when the active ingredient itself remains squarely within permitted cosmetic concentration limits.

Why the Consequence Is Worse Than a Simple Relabel

A product found to be making drug-level claims without drug registration does not just lose its cosmetic notification, it becomes an unregistered drug under Thai law, a materially more serious enforcement category that carries its own penalty structure and reputational exposure, and one that Thai FDA's advertising surveillance actively looks for precisely because false or exaggerated cosmetic claims are one of the more visible forms of consumer-facing non-compliance. Removing a product from shelves or from an e-commerce platform after an advertising enforcement action is also a materially worse commercial outcome than catching the claim during copywriting, since it typically comes with public notice and carries forward into how a regulator treats the brand's subsequent filings.

Building Claims That Stay on the Right Side of the Line

The safest practice for any brand operating close to this boundary is to write marketing copy around observable, appearance-level outcomes, smoother, softer, brighter, reduced appearance of, rather than verbs that imply a physiological correction, treat, cure, repair, regrow, reverse. Where a formulation's actual efficacy data supports a therapeutic-sounding claim, the answer is not to soften the language until it sounds cosmetic, it is to register the product as a drug and market it accordingly, because Thai FDA's enforcement risk scales with the gap between a product's actual formulation and its claimed effect, not with how carefully the copy was worded to sound cosmetic. Getting this right at the formulation and claims-strategy stage, before a product is notified, is far cheaper than reworking marketing after an enforcement notice.

DeeMED reviews both formulation and claims language together as part of our cosmetics classification work, precisely because the two cannot be assessed separately without missing exactly the kind of boundary case described here, and because a classification error caught before notification is a formulation adjustment, while one caught after is an enforcement problem.